Utility of nintedanib for severe idiopathic pulmonary fibrosis: a single-center retrospective study

INTRODUCTION: The INPULSIS-ON trial demonstrated that nintedanib reduced decline in forced vital capacity (FVC) and low pulmonary function (%FVC < 50%) of patients with idiopathic pulmonary fibrosis (IPF). However, there is no sufficient evidence in real world. OBJECTIVES: Reveal the utility and...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Drug Des Devel Ther
Autors principals: Abe, Mitsuhiro, Tsushima, Kenji, Sakayori, Masashi, Suzuki, Kenichi, Ikari, Jun, Terada, Jiro, Tatsumi, Koichiro
Format: Artigo
Idioma:Inglês
Publicat: Dove Medical Press 2018
Matèries:
Original Research
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6186773/
https://ncbi.nlm.nih.gov/pubmed/30349191
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/DDDT.S179427
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars